M&A Deal Summary |
|
|---|---|
| Date | 2013-01-02 |
| Target | BioVectra |
| Sector | Life Science |
| Buyer(s) | Questcor Pharmaceuticals |
| Deal Type | Add-on Acquisition |
| Deal Value | 50M CAD |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1990 |
| Sector | Life Science |
Questcor Pharmaceuticals, Inc. is a biopharmaceutical company that provides drugs for the treatment of autoimmune and inflammatory disorders.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 3 |
| Sector: Life Science M&A | 1 of 2 |
| Type: Add-on Acquisition M&A Deals | 1 of 1 |
| State: Prince Edward Island M&A | 1 of 1 |
| Country: Canada M&A | 1 of 1 |
| Year: 2013 M&A | 1 of 2 |
| Size (of disclosed) | 1 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2006-05-05 |
Doral
United States Doral (MedPointe) is a product of MedPointe Pharmaceuticals, Inc. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2013-06-11 |
Rights to Synacthen
United States Synacthen® and Synacthen Depot® in certain countries outside the U.S. Available in more than forty countries for multiple indications, Synacthen (tetracosactide) is a synthetic 24 amino acid melanocortin receptor agonist. Synacthen Depot is a depot formulation of Synacthen. The products are approved outside the U.S. for certain autoimmune and inflammatory conditions, but have never been developed or approved for patients in the U.S. |
Buy | $60M |
